Details

Autor(en) / Beteiligte

• Nigro, Alessandra
• Frattaruolo, Luca
• Fava, Mariarosa
• De Napoli, Ilaria
• Greco, Marianna
• Comandè, Alessandra
• De Santo, Marzia
• Pellegrino, Michele
• Ricci, Elena
• Giordano, Francesca
• Perrotta, Ida
• Leggio, Antonella
• Pasqua, Luigi
• Sisci, Diego
• Cappello, Anna Rita
• Morelli, Catia

Titel

Bortezomib-Loaded Mesoporous Silica Nanoparticles Selectively Alter Metabolism and Induce Death in Multiple Myeloma Cells

Ist Teil von

• Cancers, 2020-09, Vol.12 (9), p.2709

Ort / Verlag

Switzerland: MDPI AG

Erscheinungsjahr

2020

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• A mesoporous silica-based nanodevice bearing the antineoplastic drug bortezomib (BTZ), whose release is triggered in acidic environment and grafted with folic acid (FOL) as a targeting function (FOL-MSN-BTZ) was tested on folate receptor overexpressing (FR+) multiple myeloma (MM) cells and on FR negative (FR-) normal cells. FOL-MSN-BTZ efficacy studies were conducted by means of growth experiments, TEM, TUNEL assay and Western Blotting analysis (WB). Metabolic investigations were performed to assess cells metabolic response to MSNs treatments. FOL-MSN-BTZ exclusively killed FR+ MM cells, leading to an apoptotic rate that was comparable to that induced by free BTZ, and the effect was accompanied by metabolic dysfunction and oxidative stress. Importantly, FOL-MSN-BTZ treated FR- normal cells did not show any significant sign of injury or metabolic perturbation, while free BTZ was still highly toxic. Notably, the vehicle alone (MSN-FOL) did not affect any biological process in both tested cell models. These data show the striking specificity of FOL-MSN-BTZ toward FR+ tumor cells and the outstanding safety of the MSN-FOL vehicle, paving the way for a future exploitation of FOL-MSN-BTZ in MM target therapy.